secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001104659-23-091407
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio reports Q2 2023 cash of $112.8M; advancing ZB-106 to Phase 2 in 2H 2024
--------------------------------------------------------------------------------

- Cash and equivalents $112.8M at June 30, 2023, up from $1.6M at Dec 31, 2022; sufficient to fund operations through 2026.
- R&D expenses $28.2M in Q2 2023 vs $0.1M in Q2 2022, driven by ZB-106 license from Eli Lilly.
- G&A expenses $5.7M in Q2 2023 vs $0.8M in Q2 2022, due to higher compensation and legal/accounting costs.
- Pipeline: ZB-106 Phase 2 trials for systemic sclerosis and hidradenitis suppurativa expected to start in 2H 2024; ZB-168 and ZB-880 Phase 2 trials in 2024.
- Completed ~$80M private placement in June 2023; joined Russell 2000/3000 indexes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465923091407/0001104659-23-091407-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465923091407/tm2323743d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-091407

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer